A team of researchers at Roswell Park Comprehensive Cancer Center, led by Dhyan Chandra, Ph.D., has discovered a new ...

【导读】随机3期CHART试验（NCT03520478）显示，与比卡鲁胺（BIC）-ADT相比，雷珠鲁胺（REZ）加雄激素剥夺疗法（ADT）治疗高体积、转移性、激素敏感性前列腺癌（mHSPC）可显著提高无放射进展生存期和总生存期。2024年12月16 ...

引言前列腺癌是全球男性中最常见的恶性肿瘤之一，尤其是晚期转移性去势抵抗性前列腺癌（mCRPC）。尽管免疫检查点抑制剂（ICIs）已被证明对多种癌症具有显著疗效，但对于mCRPC患者来说，这一治疗策略的效果却不尽人意。这背后的原因复杂且多样，而肿瘤微环 ...

Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat.

Candel’s trial was conducted under the FDA’s Special Protocol Assessment program, meaning that its data could be used as a ...

The NCCN has endorsed the Prolaris prostate cancer prognostic test, reinforcing its position as a critical tool in prostate ...

PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...

By Dr. Priyom Bose, Ph.D. A comprehensive review highlights the progress, challenges, and future prospects of prostate cancer ...

Prostate cancer remains a global health challenge, ranking as the second most commonly diagnosed cancer among men. Although ...

Prostate cancer (PCa) is a common malignancy affecting the male genitourinary system. Standard treatments, such as androgen deprivation therapy (ADT), often prove ineffective for patients with ...

Standing Fixture in the Guidelines for 10th Year RunningSALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a ...

Prostate cancer remains a global health challenge, ranking as the second most commonly diagnosed cancer among men. Although treatments like androgen ...